← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $168B	3,268	+180	+6%	$198B
2	2 Eli Lilly LLY $1.12T	2,671	+186	+7%	$287B
3	3 Amgen AMGN $235B	2,501	+177	+8%	$106B
4	4 Becton Dickinson BDX $52.8B	1,555	+49	+3%	$62.8B
5	5 McKesson MCK $116B	1,287	+93	+8%	$44.6B
6	6 Regeneron Pharmaceuticals REGN $82B	1,158	+78	+7%	$66.5B
7	7 AstraZeneca AZN $259B	1,062	+96	+10%	$34.1B
8	8 Novo Nordisk NVO $173B	1,048	+141	+16%	$19.3B
9	9 Conagra Brands CAG $6.77B	879	+76	+9%	$15.1B
10	10 ResMed RMD $34.1B	730	+62	+9%	$19.7B
11	11 Lamb Weston LW $7.47B	686	+91	+15%	$11.3B
12	12 West Pharmaceutical WST $27B	637	0	0%	$16.2B
13	13 DELISTED CATALENT, INC. CTLT	485	-21	-4%	$8.34B
14	14 DaVita DVA $12.1B	444	+3	+0.7%	$5.75B
15	15 Embecta EMBC $365M	443	-18	-4%	$1.45B
16	16 Teva Pharmaceutical Industries Limited TEVA $47.9B	421	-9	-2%	$5.04B
17	17 Inspire Medical Systems INSP $2.03B	340	+39	+13%	$7.1B
18	TWNK 18 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	285	+29	+11%	$2.86B
19	19 BellRing Brands BRBR $1.05B	282	+7	+3%	$3.27B
20	20 Medifast MED $135M	277	+14	+5%	$1.05B
21	21 Opko Health OPK $1.2B	219	-2	-0.9%	$214M
22	22 Accendra Health ACH $20.1M	217	-8	-4%	$1.41B
23	23 Herbalife HLF $1.53B	216	+15	+7%	$1.55B
24	24 Amphastar Pharmaceuticals AMPH $1.12B	211	+6	+3%	$764M
25	25 AdaptHealth AHCO $852M	192	+9	+5%	$2.04B